Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

736 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease.
Prvulovic D, Bokde AL, Faltraco F, Hampel H. Prvulovic D, et al. Among authors: hampel h. Prog Neurobiol. 2011 Dec;95(4):557-69. doi: 10.1016/j.pneurobio.2011.05.008. Epub 2011 Jun 22. Prog Neurobiol. 2011. PMID: 21722703 Review.
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. Hampel H, et al. Brain. 2018 Jul 1;141(7):1917-1933. doi: 10.1093/brain/awy132. Brain. 2018. PMID: 29850777 Free PMC article. Review.
Precision pharmacology for Alzheimer's disease.
Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S; Alzheimer Precision Medicine Initiative (APMI). Hampel H, et al. Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16. Pharmacol Res. 2018. PMID: 29458203 Review.
Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment.
Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, Moeller HJ, Teipel SJ, Ernst A, Bergmann A, Hampel H. Buerger K, et al. Among authors: hampel h. J Clin Psychiatry. 2011 Apr;72(4):556-63. doi: 10.4088/JCP.09m05872oli. Epub 2010 Nov 2. J Clin Psychiatry. 2011. PMID: 21208578
Cognitive intervention in Alzheimer disease.
Buschert V, Bokde AL, Hampel H. Buschert V, et al. Among authors: hampel h. Nat Rev Neurol. 2010 Sep;6(9):508-17. doi: 10.1038/nrneurol.2010.113. Epub 2010 Aug 17. Nat Rev Neurol. 2010. PMID: 20717104 Review.
Galantamine for Alzheimer's disease.
Prvulovic D, Hampel H, Pantel J. Prvulovic D, et al. Among authors: hampel h. Expert Opin Drug Metab Toxicol. 2010 Mar;6(3):345-54. doi: 10.1517/17425251003592137. Expert Opin Drug Metab Toxicol. 2010. PMID: 20113148 Review.
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study.
Bokde AL, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, Möller HJ, Hampel H. Bokde AL, et al. Among authors: hampel h. J Clin Psychopharmacol. 2009 Apr;29(2):147-56. doi: 10.1097/JCP.0b013e31819a8f2e. J Clin Psychopharmacol. 2009. PMID: 19512976 Clinical Trial.
Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.
Teipel SJ, Drzezga A, Bartenstein P, Möller HJ, Schwaiger M, Hampel H. Teipel SJ, et al. Among authors: hampel h. Psychopharmacology (Berl). 2006 Jul;187(1):86-94. doi: 10.1007/s00213-006-0408-1. Epub 2006 Jun 1. Psychopharmacology (Berl). 2006. PMID: 16767418 Clinical Trial.
736 results
Jump to page
Feedback